Press release

Guerbet expands portfolio with microcatheters and guidewires
for interventional imaging and embolization
Villepinte, France, March 7th, 2022 - Guerbet (FR0000032526 GBT), a global leader in medical
imaging, announces it will more than double its line of microcatheters and launch a new line ofguidewires, resulting in a broad range of interventional imaging and embolization solutions
available.
The company obtained its original offering of 18 references of SeQure® and DraKon™
microcatheters as part of their acquisition of Accurate Medical Therapeutics in 2018. It received
the CE mark in April 2019, and was FDA cleared in 2018. Guerbet now expands the portfolio,adding 20 versions for a total of 38, and launching a new line of Axessio™ guidewires with twodiameters. A limited market evaluation began in the United States during the fourth quarter of2021, paving the way for a commercial launch rollout in Q2 2022 in select markets.
«The positive feedback we’ve received during the limited market release of our line extension has
reinforced Guerbet’s decision to expand available tools to the healthcare professionals for various
embolization procedures, » affirms David Hale, Chief Executive Officer. «This year marks our40th anniversary in interventional radiology. We’re proud of that, but we consider it just thebeginning. We’ve never been more dedicated to continuous growth and innovation to help
interventional radiology physicians to meet an even greater number of patient needs. »Both the SeQure® and DraKon™ technologies offer interventional radiologists optimized
navigation capabilities which is expected to enable access to difficult anatomies and reach farther.
Additionally, SeQure® is the only reflux control microcatheter enabling a fluid barrier technology
for flow directed embolization. The new models are designed to deliver more targeted treatment
and use a wider range of beads, from extra-small to large1,2.
«Innovation means everything to us, because it means everything to our physician partners andto their patients» explains Jean-François Blanc, Senior VP, Interventional Imaging. «The more
we see the results, the more we see opportunity to improve lives, and we just want to keep
pushing forward. With strategic acquisitions that helped create a unique toolkit of microcatheters
and this latest portfolio extension, we’re advancing options for the interventional radiology
community. »Guerbet is offering a Digital Launch Event to introduce the line extension on March 12th, 2022.
Find information and register for the event, including replays, peer learning, and on-demandcontent: https://launchevent.guerbet.com

1

Test Report TR-056 & TR-072 internal data on file. Beads Compatibility Test Report. Bench Tests results may notnecessarily be indicative of clinical performance.
2
Test Report TR-057 internal data on file. Beads Reflux Test Report. Bench Tests results may not necessarily beindicative of clinical performance.

Press release
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose.
We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceuticalproducts, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A
pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously
innovate and devote 10% of our sales to research and development in five centers in France, Israel,
and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated€732 million in revenue in 2021. For more information, please visit www.guerbet.com.

About SeQure®, DraKon™ and Axessio™
DraKon™ and SeQure® microcatheters are class II medical devices in the USA. Outside USA,
DraKon™ and SeQure® microcatheters are class IIb medical devices. DraKon™ and SeQure®
microcatheters are intended for use by interventional radiologists and interventional oncologists for theinfusion of contrast media into all peripheral vessels and for drug infusion in intra-arterial therapy, andinfusion of embolic materials. They should not be used in cerebral vessels. Notified Body: MedCert0482. Manufacturer: Accurate Medical Therapeutics Ltd. EC Rep: Guerbet. DraKon™ is trademark andSeQure® is a registered trademark of Guerbet Group or its affiliates.
Axessio™ Guidewire are class II medical devices in the USA. Outside USA, Axessio™ Guidewire areclass III medical device intended for use by physicians to introduce percutaneous intravascularcatheters. They should not be used in cerebral vasculature, or in patients judged not acceptable for
percutaneous intervention (PCI). Notified Body: NSAI 0050. Manufacturer: Brivant Ltd. Distributed in theEU and USA by Guerbet. Axessio™ is a registered trademark of Accurate Medical Therapeutics Ltd.
Any performance specifications are believed to be reliable and are the sole responsibility of the legal
manufacturer Brivant Ltd.
For complete information about precautions and optimal usage conditions for these medical devices, werecommend consulting the instructions for use supplied with each device or with your local Guerbet
representative(s). Information for use only in countries with applicable health authority registrations.
Registration and availability may vary according to countries.
CAUTION: US Federal Law restricts these devices to sale by or on the order of a physician. Illustrations
for information purposes - not indicative of actual size or clinical outcome.

Forward-looking statements
This press release may contain statements of a forward-looking nature, based on assumptions andpredictions made by the management of the Guerbet group. Various known and unknown risks,
uncertainties and other factors could lead to marked differences between the future results, financial
situation, development and performances of the company, and the estimates made here. These factors
include those mentioned in the public reports of Guerbet, available on its website www.guerbet.com.
The company assumes no responsibility whatsoever in relation to the updating of these forward-looking
statements, or how they correspond to future events or developments.

Media Relations
Guerbet Global
ACTIFIN
Marie-Ji-In PRADERE+33 (0)1 56 88 11 21 / mpradere@actifin.fr

Mars 2022 - I22001139 - GU02220024